WEBSITE BSE:544562 NSE: ADVANCE Inc. Year: 2002 Industry: Pesticides & Agrochemicals My Bucket: Add Stock
Last updated: 15:58
Advance Agrolife Ltd. is an agrochemical company based in Jaipur, Rajasthan that manufactures and distributes a wide range of crop‑protection products — including insecticides, herbicides, fungicides, plant‑growth regulators, micro‑nutrient fertilizers and bio‑fertilizers. It serves mainly as a B2B supplier: selling both technical‑grade active ingredients and finished formulation‑grade products to large agricultural/agrochemical corporate customers, who then distribute them further. The company runs three integrated manufacturing ...Read More
Advance Agrolife Ltd. is an agrochemical company based in Jaipur, Rajasthan that manufactures and distributes a wide range of crop‑protection products — including insecticides, herbicides, fungicides, plant‑growth regulators, micro‑nutrient fertilizers and bio‑fertilizers. It serves mainly as a B2B supplier: selling both technical‑grade active ingredients and finished formulation‑grade products to large agricultural/agrochemical corporate customers, who then distribute them further. The company runs three integrated manufacturing facilities and has built a substantial production capacity. In FY 2025, Advance Agrolife achieved revenue of around ₹502 crore, marking healthy growth; profitability and return ratios (ROE, ROCE) are competitive, reflecting operating efficiency. The firm holds hundreds of product registrations — enabling a diversified portfolio across various crops and seasons — and has a substantial distribution footprint across many Indian states plus some exports. Advance Agrolife is focused on backward integration (producing technical‑grade chemicals in‑house) to reduce dependence on external suppliers, while expanding its formulation‑grade output. Its strengths lie in diversified agrochemical products, integrated manufacturing, established customer relationships, and growing scale. However, because much of its revenue comes from a few large B2B customers and demand is linked to crop cycles and regulatory environment, performance remains sensitive to client concentration, commodity/chemical‑pricing volatility, and agro‑policy shifts ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹718 Cr.
Stock P/E 28
P/B 2.2
Current Price ₹111.7
Book Value ₹ 50
Face Value 10
52W High ₹154
Dividend Yield 0%
52W Low ₹ 84.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Net Sales | 132 | 167 | 113 | 169 | 213 | 133 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Income | 132 | 167 | 113 | 169 | 213 | 134 |
| Total Expenditure | 119 | 144 | 107 | 152 | 187 | 125 |
| Operating Profit | 13 | 23 | 7 | 17 | 26 | 9 |
| Interest | 1 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 10 | 20 | 3 | 13 | 21 | 4 |
| Provision for Tax | 3 | 6 | 1 | 4 | 5 | 1 |
| Profit After Tax | 7 | 14 | 3 | 9 | 16 | 3 |
| Adjustments | -0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 7 | 14 | 3 | 9 | 16 | 3 |
| Adjusted Earnings Per Share | 1.6 | 0.3 | 0.1 | 2 | 3.5 | 0.5 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 251 | 398 | 456 | 502 | 628 |
| Other Income | 2 | 0 | 1 | 1 | 1 |
| Total Income | 253 | 398 | 457 | 503 | 629 |
| Total Expenditure | 237 | 373 | 417 | 455 | 571 |
| Operating Profit | 16 | 25 | 40 | 48 | 59 |
| Interest | 2 | 3 | 4 | 5 | 6 |
| Depreciation | 2 | 2 | 3 | 8 | 10 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 12 | 20 | 33 | 35 | 41 |
| Provision for Tax | 3 | 5 | 9 | 10 | 11 |
| Profit After Tax | 9 | 15 | 25 | 26 | 31 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 9 | 15 | 25 | 26 | 31 |
| Adjusted Earnings Per Share | 2 | 3.3 | 5.5 | 5.7 | 6.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 10% | 26% | 0% | 0% |
| Operating Profit CAGR | 20% | 44% | 0% | 0% |
| PAT CAGR | 4% | 42% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 29% | 34% | 32% | 32% |
| ROCE Average | 27% | 33% | 31% | 31% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 36 | 51 | 75 | 101 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 3 | 6 | 14 | 15 |
| Other Non-Current Liabilities | 0 | 0 | -0 | 0 |
| Total Current Liabilities | 79 | 123 | 170 | 235 |
| Total Liabilities | 119 | 179 | 259 | 351 |
| Fixed Assets | 17 | 23 | 40 | 66 |
| Other Non-Current Assets | 1 | 1 | 11 | 12 |
| Total Current Assets | 101 | 156 | 208 | 272 |
| Total Assets | 119 | 179 | 259 | 351 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -0 | 6 | 15 | 6 |
| Cash Flow from Investing Activities | -3 | -8 | -31 | -34 |
| Cash Flow from Financing Activities | 4 | 1 | 17 | 28 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 1 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 2 | 3.3 | 5.5 | 5.7 |
| CEPS(Rs) | 2.43 | 3.85 | 6.25 | 7.39 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 7.93 | 11.24 | 16.73 | 22.42 |
| Core EBITDA Margin(%) | 5.56 | 6.3 | 8.53 | 9.07 |
| EBIT Margin(%) | 5.61 | 5.72 | 8.08 | 7.74 |
| Pre Tax Margin(%) | 4.95 | 5.06 | 7.3 | 6.71 |
| PAT Margin (%) | 3.58 | 3.74 | 5.42 | 4.88 |
| Cash Profit Margin (%) | 4.37 | 4.36 | 6.17 | 6.33 |
| ROA(%) | 7.57 | 9.98 | 11.29 | 8.41 |
| ROE(%) | 25.18 | 34.46 | 39.3 | 29.11 |
| ROCE(%) | 24.78 | 34.35 | 37.5 | 27.02 |
| Receivable days | 96.1 | 78.22 | 99.13 | 106.46 |
| Inventory Days | 43.02 | 31.36 | 35.11 | 47.46 |
| Payable days | 94.9 | 82.26 | 111.6 | 136.5 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.1 | 0.07 | 0.11 | 0.24 |
| EV/Core EBITDA(x) | 1.57 | 1.17 | 1.22 | 2.54 |
| Net Sales Growth(%) | 0 | 58.65 | 14.6 | 10.17 |
| EBIT Growth(%) | 0 | 61.82 | 61.78 | 10.34 |
| PAT Growth(%) | 0 | 65.4 | 66.34 | 3.66 |
| EPS Growth(%) | 0 | 65.4 | 66.34 | 3.66 |
| Debt/Equity(x) | 0.59 | 0.5 | 0.6 | 0.79 |
| Current Ratio(x) | 1.27 | 1.27 | 1.22 | 1.16 |
| Quick Ratio(x) | 0.9 | 0.96 | 0.94 | 0.79 |
| Interest Cover(x) | 8.52 | 8.62 | 10.41 | 7.48 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2025 | Oct 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 69.89 | 69.89 | 69.89 | 69.89 |
| FII | 6.13 | 6.13 | 4.43 | 2.58 |
| DII | 8.07 | 8.07 | 2.64 | 1.92 |
| Public | 15.9 | 15.9 | 23.04 | 25.61 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Sep 2025 | Oct 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 4.49 | 4.49 | 4.49 | 4.49 |
| FII | 0.39 | 0.39 | 0.28 | 0.17 |
| DII | 0.52 | 0.52 | 0.17 | 0.12 |
| Public | 1.02 | 1.02 | 1.48 | 1.65 |
| Others | 0 | 0 | 0 | 0 |
| Total | 6.43 | 6.43 | 6.43 | 6.43 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
